Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Status:
Recruiting
Trial end date:
2022-02-03
Target enrollment:
Participant gender:
Summary
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients
age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has
spread to other places in the body.